The distribution of T‐cell subsets and the expression of immune checkpoint receptors and ligands in patients with newly diagnosed and relapsed acute myeloid leukemia
Patrick Williams(The University of Texas MD Anderson Cancer Center), Naval Daver(The University of Texas MD Anderson Cancer Center), Carlos E. Bueso‐Ramos(The University of Texas MD Anderson Cancer Center), Jörge E. Cortes(Augusta University Health), Marina Konopleva(Albert Einstein College of Medicine), Gheath Alatrash(Mayo Clinic), Zainab Alhamal(The University of Texas MD Anderson Cancer Center), Katherine R. Calvo(National Institutes of Health Clinical Center), James P. Allison(The University of Texas MD Anderson Cancer Center), Elias Jabbour(The University of Texas MD Anderson Cancer Center), Wilmer Flores(The University of Texas MD Anderson Cancer Center), Guillermo Garcia‐Manero(The University of Texas MD Anderson Cancer Center), Christopher S. Hourigan(National Heart Lung and Blood Institute), Jorge Blando(AstraZeneca (Netherlands)), Lianchun Xiao(The University of Texas MD Anderson Cancer Center), Padmanee Sharma(The University of Texas MD Anderson Cancer Center), Karolyn A. Oetjen(Saint Louis University), Pallavi Galera(National Institutes of Health Clinical Center), Sreyashi Basu(The University of Texas MD Anderson Cancer Center), Michael Andreeff(The University of Texas MD Anderson Cancer Center), Hagop M. Kantarjian(The University of Texas MD Anderson Cancer Center), Juliana Hidalgo Lopez(The University of Texas MD Anderson Cancer Center), Farhad Ravandi(The University of Texas MD Anderson Cancer Center), Steve Kornblau(The University of Texas MD Anderson Cancer Center), Jing Ning(The University of Texas MD Anderson Cancer Center)
Cited by 339
Related Papers
International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data
|Blood|2022|2.7k
Immunologic Correlates of the Abscopal Effect in a Patient with Melanoma
|New England Journal of Medicine|2012|2.1k
Durable Remissions with Ivosidenib in <i>IDH1</i> -Mutated Relapsed or Refractory AML
|New England Journal of Medicine|2018|1.4k
The Prioritization of Cancer Antigens: A National Cancer Institute Pilot Project for the Acceleration of Translational Research
|Clinical Cancer Research|2009|1.4k